In January 2017, an 11.5-year-old male child with autism was referred for radioiodine (RAI) therapy post total thyroidectomy for papillary thyroid carcinoma. The treatment required swallowing a RAI capsule and remaining isolated (48-72 h). Initially, obstacles to a successful treatment seemed insurmountable as he had complex needs and behavioral issues due to his autism, mild intellectual disability, and family environment. His mother was adamant that he would not be able to swallow the capsule and comply with the required isolation period. A multidisciplinary team was formed to explore options for successful treatment. Each option considered had its own risks and challenges. Behavioral therapy was considered to be the only possible option. It was pursued with regular, frequent contact between the child, his parents, and members of the team for counseling and behavioral modification, familiarization of the child with the staff, procedures, trial visits, and admission. The patient was successfully treated in October 2017.
INTRODUCTION
The 11.5-year-old child, co-slept with his mother, was not responsible for his own personal hygiene, including toileting, had a very selective diet, and was not keen to go to school. He attended a special school because of his autism but following the thyroidectomy operation had not returned to school, despite full medical recovery. He also received assistance with feeding. His mother demonstrated a reluctance to progress his independence. A multidisciplinary team was formed to work diligently with the child and mother to train him and change his and his mother's behavior.
CASE REPORT
Total thyroidectomy and adjuvant radioiodine ( 131 I) (RAI) therapy is the accepted standard treatment of patients with thyroid carcinoma but is challenging for children with behavioral issues. In fact, in a recent reported case of a child with autism spectrum disorder, RAI treatment was abandoned due to behavior-related issues and the patient was treated with sorafenib [1] as a second-line option. For our 11.5-year-old child, it became clear, from the first consultation session, that behavioral obstacles related to the child's autism, intellectual disability, and family environment needed to be overcome. The two main issues for the treatment were how to administer the RAI and how to keep the patient confined. A multidisciplinary team consisting of a nuclear medicine physician, oncologist, nuclear medicine technologist, hospital radiation safety officer (RSO), clinical psychologist, oncology nursing manager, anesthetist, and play therapist was formed to consider the various options to pursue the treatment. Options included extended general anesthesia which would have allowed the administration of the RAI in liquid form via nasogastric tube and kept the child sedated for the isolation period; the mother being allowed to stay in the room during treatment and co-sleep with the son, and treatment at home. These options were not pursued because of radiation safety issues. Transferring patient to another facility was also considered as an interstate pediatric facility had sedated younger children for 131 I meta-iodobenzylguanidine therapy. However, because of the complexity of the transfer that unfolded, this ceased to be an option. Restraint and medication were also considered as the last resorts if the parents refused life-saving treatment.
Counseling and behavioral modifications seemed the only possible option and was diligently pursued over 9 months. It involved regular and frequent contact between the clinical psychologist, nuclear medicine personnel, and the play therapist with the family. During weekly consultations with the nuclear medicine staff, the mother was encouraged not to sleep with her son and for him to trial swallowing solid medication. Visits to the therapy room [ Figure 1 ] were made on these occasions. Over time, a rapport developed between hospital staff, the child, and parents.
A diagnostic iodine ( 123 I) study performed in August 2017 demonstrated metastatic spread of his thyroid cancer. The parents realized the urgency of the treatment and the mother placed more effort in training the son to sleep alone in a separate bed and to take care of his personal hygiene. Overnight stay trials in the therapy room were organized. The initial trial was not successful but a subsequent trial was. Multiple trials at the hospital for him to swallow a placebo capsule were successful.
The patient was admitted for therapy on October 11, 2017, in a child-friendly purpose-built therapy suite [ Figure 1 ] and administered with 7989 MBq of RAI in two capsules. The patient swallowed the capsules without any issues. He had been prepared with thyroxine withdrawal for 3 weeks and a low iodine diet for 2 weeks.
The therapy suite has a shielded alcove where the mother stayed overnight. A small bed can fit in this area. For entertainment, the patient was provided with a computer connected to the Internet, Wi-Fi, iPad, X-Box, DVD, craft, and books. Other treasured items were brought from home. To delineate the therapy room from the rest of the therapy suite, he was asked to set up a barrier made of playpen extension panels. [2] He took ownership of this barrier and during the isolation period made no effort to cross the barrier which he considered was his. The parents were monitored continuously with electronic pocket dosimeters with alarms set on both dose rate and cumulative dose.
The administration of RAI was successful; however, within a few hours, the patient felt cold related to hypothyroidism. The room temperature was increased and the patient kept warm with extra blankets. He then had three episodes of vomiting at 6.7, 11.67, and 29.67 h posttreatment despite having taken anti-emetic medication. Another complication was constipation, also due to hypothyroidism.
The mother provided the main care to her son. The father was there at intermittent periods. She received a personal accumulated radiation equivalent dose of 97 µSv, while the father received 23.8 µSv and all nursing staff received 13 µSv. The RSO measured the external radiation dose rate from the patient at a distance of 3 m with a survey meter at a regular time during working hours and after the three episodes of vomiting. The external radiation dose rate curves for both raw data and exponential fitted curves are shown in Figure 2 . The corresponding whole-body retention time-activity curves are shown in Figure 3 . These data were used to estimate the activities contained in the vomita [ Figure 3 ] which were 1297, 684, and 160 MBq, respectively, at 6.7, 11.67, and 29.67 h posttreatment and the whole-body and blood doses. The total vomited activity was 2141 MBq. The whole-body dose was estimated to be 243 mGy and the blood dose calculated using the formula by Hänscheid et al. [3] and the blood volume formula by Retzlaff et al. [4] was 388 mGy. The whole-body retention activity at 48 h was 234 MBq.
The patient was discharged 47 h postadministration of the RAI.
DISCUSSION
The patient was imaged 9 days posttreatment and showed [ Figure 4 ] neck lymph node and focal pulmonary metastatic uptake as expected from the pretreatment diagnostic 123 I scans. The absorbed blood dose of 388 mGy and the whole-body retention activity at 48 h of 234 MBq were considerably less than the limit safe dose [5] of 2 Gy and whole-body retention of 4400 MBq in the absence of diffuse lung metastases or 3000 MBq with the presence of metastases at 48 h. These values indicate that, if considered necessary in a repeat RAI procedure, an activity up to 40 GBq could be administered to the patient without exceeding the blood safe dose of 2 Gy and whole-body retention of 3000 MBq with the presence of metastases at 48 h.
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